Nurix Therapeutics NRIX
NASDAQ NRIX
$16.32 +0.44 (+2.77%)
As of: Nov 11, 2026 · 3:59 PM EST

Nurix Therapeutics (NRIX) EV to CFO (2020 - 2026)

Updated

Nurix Therapeutics' (NRIX) EV to CFO stood at 4.66 in fiscal Q3 2026 (quarter ended Aug 31, 2026).

Analysis

Nurix Therapeutics (NRIX) EV to CFO (2020 - 2026) Analysis & Trends

On a TTM basis, Nurix Therapeutics' EV to CFO came in at 0.50 as of Aug 31, 2026.

  • The fiscal Q3 2026 figure is the highest quarterly EV to CFO since fiscal Q3 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Nurix Therapeutics 1.73 Bn -891.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2026 4.66
Aug 31, 2020 49.67
API Access

Nurix Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=NRIX&period=max&api_key=YOUR_API_KEY